2Malfertheiner P, M6graud F, O' Morain C, et al. Currenl concepts in the management of Helicobacter pylori infectionqhc Maastricht 2-2000 Consensus Report [J]. Aliment Pharmacol Ther, 2002, 16(2): 167-180.
3Malfertheiner P, Megraud F, O' Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht Ⅲ Consensus Report[J]. Gut, 2007, 56(6): 772-781.
4Megraud F. Update on therapeutic options for Helicobacter pylori-related diseases[J]. Curr Infect Dis Rep, 2005, 7 (2) : 115-120.
5Stoltenberg M, Martiny M, Sorensen K, et al. Histochemical tracing of bismuth in Helicobacter pylori after in vitro exposure to bismuth citrate[J]. Scand J Gastroenterol, 2001, 36 (2) : 144-148.
6Worku ML, Sidebotham RL, Karim QN. Effects of ranilidinc bismuth citrate on Helicobacter pylori motility, morphology and survival[J]. Aliment Pharmacol Tber, 1999, 13(6): 753-760.
7Fischbach LA, van Zanten SV, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti Helicobacter pylori quadruple therapies[J].Aliment Pharmacol Ther, 2004, 20(10): 1071-1082.
8Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy[J]. Helicobacter, 2007, 12 (4): 275-278.
